REGENERATION OF SURFACE ANTIGEN-NEGATIVE CELLS
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Jan 16, 2025
app pub date -
Nov 18, 2022
filing date -
Nov 18, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Provided are gene editing technologies, including specifically designed and tested guide RNA sequences for improved base editors, useful for disrupting the expression of genes, such as CD33, CD123, CD47, CD45 and CLL1, in a cell. Such methods and edited cells are useful in reducing the toxicity associated with therapies targeting such cell surface antigens, such as those for treating acute myeloid leukemia.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully